

Development of a Non-Invasive Eye Drop Treatment for Diabetic Retinopathy Targeting Ischemic Areas

FY2025 STEP2

Commercialization
Promotion Organization (main in-charge)

Vision Incubate Co., Ltd.

Principal Investigator

University of Fukui
Professor OKI, Masaya

Problem

Challenges of Anti-VEGF Drugs,
the Mainstay Treatment for
Diabetic Retinopathy

- (1) Impossible to target ischemic areas
- (2) Multiple injections of antibody drugs and high-cost
- (3) Intravitreal injection and highly invasive




Professor Oki, Masaya

Technology: Development of Novel Drug Z3-5

Reversible Epigenetics Eliminates Abnormal Vessels,
Regenerates Normal Vessels and Eliminates Ischemic Areas

- (1) Possible to target ischemic areas
- (2) Small molecule drugs and low-cost
- (3) Eye drops and less invasive



Market Size

Angiogenesis inhibitors
About \$250 billion (2023)

Retinal ischemic disease
About \$25 billion (2023)

Diabetic Retinopathy
About \$8.9 billion
(2023)

Our goal is to capture a share of
anti-VEGF drugs in the diabetic
retinopathy market

Expected establishment date: FY 2027

Target market: Global